The University of Chicago Header Logo

Connection

Mary Dolan to Cisplatin

Back to Details
This is a "connection" page, showing publications Mary Dolan has written about Cisplatin.
Mary Dolan
Connection Strength
6.054
Cisplatin
  1. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
    View in: PubMed
    Score: 0.518
  2. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clin Cancer Res. 2019 07 01; 25(13):4104-4116.
    View in: PubMed
    Score: 0.509
  3. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
    View in: PubMed
    Score: 0.492
  4. Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. J Proteome Res. 2017 11 03; 16(11):4227-4236.
    View in: PubMed
    Score: 0.458
  5. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
    View in: PubMed
    Score: 0.319
  6. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008 Nov; 327(2):442-52.
    View in: PubMed
    Score: 0.243
  7. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008 Mar; 18(3):253-62.
    View in: PubMed
    Score: 0.236
  8. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
    View in: PubMed
    Score: 0.227
  9. Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006 Jan 12; 71(3):239-47.
    View in: PubMed
    Score: 0.202
  10. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics. 2005 Apr; 6(3):303-10.
    View in: PubMed
    Score: 0.193
  11. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
    View in: PubMed
    Score: 0.186
  12. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther. 2005 Jan; 312(1):206-13.
    View in: PubMed
    Score: 0.184
  13. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy. JAMA Oncol. 2024 Jul 01; 10(7):912-922.
    View in: PubMed
    Score: 0.183
  14. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6.
    View in: PubMed
    Score: 0.182
  15. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther. 2003 Jul; 2(7):633-40.
    View in: PubMed
    Score: 0.171
  16. Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer. Cancer Med. 2023 02; 12(3):2999-3012.
    View in: PubMed
    Score: 0.162
  17. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
    View in: PubMed
    Score: 0.156
  18. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
    View in: PubMed
    Score: 0.141
  19. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768.
    View in: PubMed
    Score: 0.112
  20. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333.
    View in: PubMed
    Score: 0.109
  21. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol. 2016 08 10; 34(23):2712-20.
    View in: PubMed
    Score: 0.105
  22. Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Res. 2016 Jan; 16(1):140-8.
    View in: PubMed
    Score: 0.102
  23. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
    View in: PubMed
    Score: 0.090
  24. EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
    View in: PubMed
    Score: 0.088
  25. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
    View in: PubMed
    Score: 0.075
  26. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88.
    View in: PubMed
    Score: 0.075
  27. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
    View in: PubMed
    Score: 0.074
  28. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
    View in: PubMed
    Score: 0.072
  29. The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol. 2009 May 15; 77(10):1586-92.
    View in: PubMed
    Score: 0.063
  30. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun; 64(1):133-42.
    View in: PubMed
    Score: 0.062
  31. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 Feb; 33(1):9-23.
    View in: PubMed
    Score: 0.054
  32. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023 02; 17(1):27-39.
    View in: PubMed
    Score: 0.041
  33. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy. J Clin Oncol. 2023 04 20; 41(12):2211-2226.
    View in: PubMed
    Score: 0.041
  34. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear Hear. 2022 May/Jun; 43(3):794-807.
    View in: PubMed
    Score: 0.039
  35. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
    View in: PubMed
    Score: 0.030
  36. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72.
    View in: PubMed
    Score: 0.019
  37. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
    View in: PubMed
    Score: 0.018
  38. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.009
  39. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
    View in: PubMed
    Score: 0.007
  40. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.